Novo Nordisk's Wegovy cuts BMI by 17% in children aged 6 to 12

Phase 3 STEP Young data, published in the NEJM, show semaglutide reduced BMI by 17.4% versus a 2.2% rise with placebo at 68

A modern medical imaging scanner with visible internal components stands in a brightly lit, minimalist room with a large window, a cream armchair, a small table, and a wooden paneled wall.

Novo Nordisk has reported that once-weekly semaglutide injection, marketed as Wegovy, produced a mean BMI reduction of 17.4% in children aged 6 to under 12 with obesity, compared with a 2.2% increase in the placebo group at 68 weeks. The findings come from the phase 3 STEP Young trial, which were presented at ObesityWeek 2026 in Washington D.C. and simultaneously published in the New England Journal of Medicine.

The randomised, double-blind, placebo-controlled trial enrolled 165 children, more than 85% of whom had class II or III severe obesity at baseline. Almost 80% of those treated with semaglutide achieved a BMI reduction of 10% or more, compared with none in the placebo group. At week 68, 40.4% of children on semaglutide were no longer classified as having obesity, against 0% in the placebo arm, based on CDC growth-chart thresholds. The treatment regimen estimand, which accounts for adherence variations, showed an estimated treatment difference of 16.2 percentage points (95% CI: -19.4 to -12.9; p less than 0.001).

Clinical significance

Ania Jastreboff, Professor of Medicine and Paediatrics at Yale School of Medicine and Director of the Yale Obesity Research Centre, described the results as encouraging. "Treating obesity with semaglutide was accompanied by improvements in multiple cardiometabolic measures, suggesting that effective treatments for severe childhood obesity may shift a child's trajectory back towards one of improving weight-related health," she said.

The safety and tolerability profile was described as consistent with prior Novo semaglutide trials in paediatric and adult populations, with no unexpected concerns identified and no safety signals relating to growth or pubertal development. The most commonly reported side effects were gastrointestinal in nature, including nausea, vomiting and diarrhoea. The boxed warning applicable to the 2.4 mg formulation in adults, covering a possible risk of thyroid tumours including medullary thyroid carcinoma, also applies to this investigational use. Novo noted that semaglutide injection is not approved in the United States for children under 12, and that regulatory approval for this indication is not guaranteed.

Market and regulatory context

The STEP Young readout extends Novo's paediatric GLP-1 programme, which already includes STEP TEENS data supporting approval of semaglutide 2.4 mg in adolescents aged 12 to 17, as well as earlier liraglutide trials in both younger children and teenagers. Approval of Wegovy in the 6-to-12 age group would represent a material expansion of the addressable market; the World Obesity Federation estimated that around 177 million children and teenagers aged 5 to 19 globally were living with obesity in 2025.

The competitive landscape for paediatric obesity pharmacotherapy remains limited. No GLP-1 receptor agonist is currently approved in the United States for children under 12, and lifestyle intervention programmes alone have demonstrated modest and inconsistent outcomes in this age group. A successful regulatory filing could position Novo ahead of rivals developing oral or injectable incretin-based therapies, though any approval pathway will require close scrutiny from the FDA given the age of the population and the long-term safety questions that a 68-week trial cannot fully resolve. Investors will be watching for a formal US supplemental biologics licence application filing date and any early signals from the FDA regarding advisory committee review.